Gilead Sciences
Change company
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
IN
IE
US
US
US
US
US
US
US
US
US
AU
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
BM
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
JP
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
CA
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
Gilead Sciences (GILD) Business News
Track Gilead Sciences in real time with a live news feed covering Gilead Sciences stock news, official press releases, company announcements, and an archive of historical Gilead Sciences news. ...more
-
CalendarDateSuMoTuWeThFrSaSelected FilterNo selection
Gilead Sciences (GILD) Falls More Steeply Than Broader Market: What Investors Need to Know
TrumpRx lists many medicines at prices higher than paid in UK
Gilead Sciences, Inc. $GILD Shares Purchased by Achmea Investment Management B.V.
Gilead Sciences, Inc. $GILD Shares Purchased by Achmea Investment Management B.V.
Bank of Nova Scotia Sells 319,843 Shares of Gilead Sciences, Inc. $GILD
Bamco Inc. NY Purchases 5,500 Shares of Gilead Sciences, Inc. $GILD
Alliancebernstein L.P. Sells 258,213 Shares of Gilead Sciences, Inc. $GILD
Will GILD's Move to Acquire ACLX Boost Its Cell Therapy Franchise?
The Zacks Analyst Blog Oracle, T-Mobile, Gilead, and C&F Financial
Josh Brown: Biotech growth stocks immune to disruption risk
Gilead Sciences, Inc. (GILD) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
2 Recession-Resistant Dividend Stocks to Buy Now
Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street's Latest Biopharma Calls Explained
Gilead Sciences (GILD) Falls More Steeply Than Broader Market: What Investors Need to Know
7:00 PM | Wednesday | Mar 18, 2026
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $141.29, denoting a -2.15% move from the preceding trading day.
Read full article
Gilead Sciences (GILD) Falls More Steeply Than Broader Market: What Investors Need to Know
Zacks Investment ResearchIn the closing of the recent trading day, Gilead Sciences (GILD) stood at $141.29, denoting a -2.15% move from the preceding trading day.
Read full article
TrumpRx lists many medicines at prices higher than paid in UK
ReutersU.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those paid in the United Kingdom, according to a Reuters comparison of publicly available prices.
Read full article
Gilead Sciences, Inc. $GILD Shares Purchased by Achmea Investment Management B.V.
Defense WorldAchmea Investment Management B.V. lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 5.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission.
The fund owned 480,352 shares of the biopharmaceutical company's stock after buying an additional 24,564 shares during
Gilead Sciences, Inc. $GILD Shares Purchased by Achmea Investment Management B.V.
Defense WorldAchmea Investment Management B.V. lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 5.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission.
The fund owned 480,352 shares of the biopharmaceutical company's stock after buying an additional 24,564 shares during
Bank of Nova Scotia Sells 319,843 Shares of Gilead Sciences, Inc. $GILD
Defense WorldBank of Nova Scotia reduced its position in Gilead Sciences, Inc. (NASDAQ: GILD) by 55.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 260,374 shares of the biopharmaceutical company's stock after selling 319,843 shares during the period. Bank of
Read full article
Bamco Inc. NY Purchases 5,500 Shares of Gilead Sciences, Inc. $GILD
Defense WorldBamco Inc. NY lifted its position in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 29.7% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 24,000 shares of the biopharmaceutical company's stock after purchasing an additional 5,500 shares during the quarter.
Bamco
Alliancebernstein L.P. Sells 258,213 Shares of Gilead Sciences, Inc. $GILD
Defense WorldAlliancebernstein L.P. cut its holdings in Gilead Sciences, Inc. (NASDAQ: GILD) by 4.2% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission.
The institutional investor owned 5,886,577 shares of the biopharmaceutical company's stock after selling 258,213 shares during the quarter. Alliancebernstein L.P. owned approximately 0.47% of
Will GILD's Move to Acquire ACLX Boost Its Cell Therapy Franchise?
Zacks Investment ResearchGilead plans a $7.8B Arcellx acquisition as cell therapy sales decline, seeking full control of anito-cel to strengthen its oncology pipeline.
Read full article
The Zacks Analyst Blog Oracle, T-Mobile, Gilead, and C&F Financial
Zacks Investment ResearchOracle's AI-driven cloud surge, T-Mobile's 5G edge, and Gilead's dominant HIV franchise headline today's top analyst reports and highlight key growth drivers.
Read full article
Josh Brown: Biotech growth stocks immune to disruption risk
24/7 Wall StreetJosh Brown, CEO of Ritholtz Wealth Management, made a pointed claim on CNBC's Halftime Report this week about large-cap biotech: “These are growth stocks where you don't have to worry about disruption.
Read full article
Gilead Sciences, Inc. (GILD) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Seeking AlphaGilead Sciences, Inc. (GILD) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Read full article
2 Recession-Resistant Dividend Stocks to Buy Now
The Motley FoolThese two healthcare leaders have businesses built to withstand economic downturns. Both have grown their dividends at a pretty good clip over the past decade.
Read full article
Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street's Latest Biopharma Calls Explained
24/7 Wall StreetWall Street is drawing fresh lines across the large-cap biopharma landscape. Jefferies initiated coverage on Gilead Sciences Inc.
Read full article